• INDEPTH project established as a result of a US$17 million grant provided by the Bill & Melinda Gates Foundation.
   

• The MCTA is a strong, African-led institution which aims to strengthen clinical trial capacity, share results of real, on-the-ground trial activities and to codify best practices.
   

• It will enable African institutions and scholars to participate fully in the development of new tools for addressing malaria and in conducting interventions against malaria, and will create a long-term partnership between African and Northern institutionsfrican-led institution

• Initially, MCTA will work in partnership with two other Gates Foundation grantees, the Malaria Vaccine Initiative (MVI) and the Medicines for Malaria Venture (MMV), to train personnel and improve facilities and infrastructure to ensure the successful execution of clinical trials in 9 countries across Africa (Mozambique, Gabon, Tanzania, Nigeria, Malawi, Ghana, The Gambia, Kenya and Senegal) where trial sites have been identified for participation or are already participating in clinical trials.
   

• In the long term, the objective is to identify, support, strengthen, mentor and network trial sites to facilitate their self-sustainability, ensuring that trial sites remain functional after the end of a trial and thus increasing the number of sites in Africa which will be ready to conduct trials for malaria vaccine and drug interventions.
   

• MCTA will ensure that the trial sites are equipped with proper management, the tools to identify, hire and train staff, database and communications systems and transparent financial systems.

MCTA Initial Partners: MMV, MVI, AMANET